Tag: avrobio
January 18, 2019
AVROBIO Announces Acceptance of Investigational New Drug (IND) Application
AVROBIO (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy candidate for cystinosis, AVR-RD-04, is cleared...
November 1, 2018
VIDEO — Life Science Update October 2018
With October behind us, the Investing News Network (INN) has brought together some of the biggest stories in the life...
October 1, 2018
Avrobio’s Share Price Drops 50 Percent Amid Clinical Trial Updates
On Monday, the company released updates on two drugs in ongoing trials. The first drug is in a Phase 1... October 1, 2018
AVROBIO Receives No Objection to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher Disease
AVROBIO (Nasdaq:AVRO) a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today... October 1, 2018
